ALPMF News and Press, Astellas Pharma Inc From 10/29/20

Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy,...

The FDA has designated Fast Track status to Astellas Pharma's (ALPMF) imaging agent ASP5354.The Fast Track Designation Program aims to expedite the development and review of potential treatments.ASP5354 is an optical imaging agent underdevelopment as a surgical adjunct to lessen the likelihoo...

The FDA designates Astellas Pharma's (ALPMF) ASP0367 for Fast Track review for the potential treatment of primary mitochondrial myopathies, a group of disorders caused by mutations within the DNA of mitochondria.Phase 1-stage ASP0367 selectively modulates a nuclear hormone receptor called PPA...

Astellas Pharma (ALPMF) and iota Biosciences have entered into a Merger Agreement pursuant to which Astellas will acquire iota. Through this deal, Astellas will acquire iota’s bioelectronics technology to accelerate its Rx+ business and explore other applications for new targ...

Seagen (SGEN) and its collaborating partner Astellas Pharma (ALPMF) have announced topline results from the second cohort of Phase 2 EV-201 trial, evaluating its antibody-drug conjugate Pacdev (enfortumab vedotin-ejfv) for patients with locally advanced/metastatic urothelial ca...

Virios Therapeutics has filed to raise $30 million in an IPO of its common stock. The firm is developing a proprietary formulation for the treatment of fibromyalgia, a pain condition. VIRI has achieved intriguing early efficacy results, received fast track review status and the IP...

Astellas Pharma ( OTCPK:ALPMF ) and Seattle Genetics (NASDAQ: SGEN ) have announced that a Phase 3 (EV-301) trial of PADCEV (enfortumab vedotin-ejfv) met its primary endpoint of overall survival (OS) compared to chemotherapy, in locally advanced/metastatic urothe...

Quick Take Virios Therapeutics ( VIRI ) has filed to raise $34.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a drug treatment for fibromyalgia, a nerve pain condition. VIRI has generated interesting early stage efficacy r...

BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...

Astellas Pharma ( OTCPK:ALPMF ) unit Audentes Therapeutics reports the third death in its Phase 1/2 ASPIRO study evaluating gene therapy AT132 in patients with X-linked myotubular myopathy , a rare serious and life-threatening inherited disorder characterized by weakness in the skeletal...